ProstaScint

In-111 Capromab Pendetide (ProstaScint)

This radiotracer, which binds preferentially to prostate membrane specific antigen (PMSA), is used to localize protate adenocarcinoma.

Go back to Oncology (Nuclear) imaging.

Normal biodistribution

Coming soon

Resources

Wong TZ et al. "ProstaScint (Capromab Pendetide) Imaging Using Hybrid Gamma Camera–CT Technology." AJR 2005; 184(2):676-680.

Gordon L. "Prostate Imaging" Presentation on ProstaScint. 2008.

This site is educational in nature and for nuclear medicine, radiology and medical professionals in the U.S., contains user contributed content, and material that may be confusing to a lay audience. Readers are asked to check the most current information on nuclear medicine techniques as this website may not be all-encompassing or up-to-date. It is solely the responsibility of the professional to practice nuclear medicine based on his or her experience and knowledge of the patient. To the fullest extent of the law, neither the publisher or authors assume any liability for any consequences to persons or property arising out of or related to any use of the material in this website.